113 related articles for article (PubMed ID: 22684442)
1. The right roadmap for personalized tests.
Bourzac K
Cancer Discov; 2012 Jun; 2(6):478. PubMed ID: 22684442
[No Abstract] [Full Text] [Related]
2. Direct-to-consumer genetic testing: the need to get retail genomics right.
Schickedanz AD; Herdman RC
Clin Pharmacol Ther; 2009 Jul; 86(1):17-20. PubMed ID: 19536118
[No Abstract] [Full Text] [Related]
3. Is there an imperative for generic profiling to hasten the age of personalized medicine.
Somberg J
Am J Ther; 2012 May; 19(3):163. PubMed ID: 22565850
[No Abstract] [Full Text] [Related]
4. Genomics, personalized medicine and cancer practice.
Dancey J
Clin Biochem; 2012 Apr; 45(6):379-81. PubMed ID: 22424082
[No Abstract] [Full Text] [Related]
5. The clinical potential and challenges of sequencing cancer genomes for personalized medical genomics.
Cloonan N; Waddell N; Grimmond SM
IDrugs; 2010 Nov; 13(11):778-81. PubMed ID: 21046525
[TBL] [Abstract][Full Text] [Related]
6. Personalized medicine: an introduction to the ethical challenges.
Fleck LM
Urol Oncol; 2014 Feb; 32(2):186. PubMed ID: 24183192
[No Abstract] [Full Text] [Related]
7. Impact of genomics on personalized cancer medicine.
Arteaga CL; Baselga J
Clin Cancer Res; 2012 Feb; 18(3):612-8. PubMed ID: 22298893
[TBL] [Abstract][Full Text] [Related]
8. Duke scandal highlights need for genomics research criteria.
Goozner M
J Natl Cancer Inst; 2011 Jun; 103(12):916-7. PubMed ID: 21693754
[No Abstract] [Full Text] [Related]
9. Transcript profiling towards personalised medicine in rheumatoid arthritis.
Verweij CL
Neth J Med; 2009 Dec; 67(11):364-71. PubMed ID: 20009112
[TBL] [Abstract][Full Text] [Related]
10. Biologics: Personalized drugs should cut care costs.
Malik NN
Nature; 2012 May; 485(7400):582. PubMed ID: 22660309
[No Abstract] [Full Text] [Related]
11. Personalized medicine and the need for decision support systems.
Denecke K; Spreckelsen C
Stud Health Technol Inform; 2013; 186():41-5. PubMed ID: 23542964
[TBL] [Abstract][Full Text] [Related]
12. Dealing with the evidence dilemma in genomics and personalized medicine.
Khoury MJ
Clin Pharmacol Ther; 2010 Jun; 87(6):635-8. PubMed ID: 20485318
[TBL] [Abstract][Full Text] [Related]
13. From genomic landscapes to personalized cancer management-is there a roadmap?
Swanton C; Caldas C
Ann N Y Acad Sci; 2010 Oct; 1210():34-44. PubMed ID: 20973797
[TBL] [Abstract][Full Text] [Related]
14. Company profile: Sequenom, Inc.
Cantor CR
Pharmacogenomics; 2012 Apr; 13(5):529-31. PubMed ID: 22462745
[TBL] [Abstract][Full Text] [Related]
15. The CDC's EGAPP initiative: evaluating the clinical evidence for genetic tests.
Berg AO
Am Fam Physician; 2009 Dec; 80(11):1218. PubMed ID: 19961131
[No Abstract] [Full Text] [Related]
16. Race, risk, and recreation in personal genomics: the limits of play.
Lee SS
Med Anthropol Q; 2013 Dec; 27(4):550-69. PubMed ID: 24214161
[TBL] [Abstract][Full Text] [Related]
17. Personalized medicine gets practical.
Sanders D; Kmiecik T
Healthc Inform; 2009 May; 26(5):50-1. PubMed ID: 19514241
[No Abstract] [Full Text] [Related]
18. Clinical genomic testing: getting it right.
Douglas PS; Ginsburg GS
J Cardiovasc Transl Res; 2008 Mar; 1(1):17-20. PubMed ID: 20559953
[No Abstract] [Full Text] [Related]
19. Direct-to-consumer marketing of genetic and genomic tests.
Oncology Nursing Society
Oncol Nurs Forum; 2010 Jul; 37(4):385. PubMed ID: 20591798
[No Abstract] [Full Text] [Related]
20. The personalized medicine revolution: getting it right for children.
Burckart GJ; Green DJ
Pediatr Transplant; 2012 Sep; 16(6):530-2. PubMed ID: 22225514
[No Abstract] [Full Text] [Related]
[Next] [New Search]
